Infinity Pharmaceuticals Inc. (INFI) Reports Second Quarter 2013 Financial Results and Provides Company Update
8/8/2013 7:54:32 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported its second quarter 2013 financial results and provided an update on its clinical pipeline. Infinity today announced that, in the fourth quarter of 2013, it expects to initiate a Phase 3 trial of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Hey, check out all the research scientist jobs. Post your resume today!